Leukemia research · 2025
Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Danis Ryan, Bujarski Sean, Yashar David, Del Dosso Ashley, Moore Jonathan, Mettias Sarah, Berenson James R
Аннотация
BACKGROUND: Multiple myeloma (MM) is an incurable B cell malignancy requiring complex treatments with a variety of drugs. Patients often become refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies (mAb), and termed triple class refractory (TCR), associated with a poor prognosis.
OBJECTIVE: We performed a retrospective analysis of data regarding the outcomes of TCR MM patients at a single clinic specializing in the care of multiple myeloma patients.
PATIENTS AND METHODS: A retrospective chart review was conducted among 117 patients with TCR MM at a single clinic. Patients' progression-free survival (PFS), overall survival (OS), cytogenetics, lines of prior therapy (LOT), and first treatment they received after the development of TCR disease were determined.
RESULTS: The median time from diagnosis to development of TCR disease from diagnosis was 47 months (range: 1.5-191.0; n = 104) and the median LOT prior to TCR disease development was 5 (range: 2-13; n = 117). From the development of TCR disease, patients in our study showed a median OS of 18.9 months (range: 0.03-60.0) and a median PFS of 3.1 months (range: 0.1-55.1). The most commonly utilized first treatment regimens used after TCR disease development were mAb-containing combinations (n = 42). Venetoclax-based regimens showed the longest median PFS at 12.4 months (n = 14).
CONCLUSIONS: This median OS of 18.9 months recorded at a single clinic provides real-world data regarding the survival of TCR MM patients highlighting the need for improvement in prognosis for this subset of patients.
OBJECTIVE: We performed a retrospective analysis of data regarding the outcomes of TCR MM patients at a single clinic specializing in the care of multiple myeloma patients.
PATIENTS AND METHODS: A retrospective chart review was conducted among 117 patients with TCR MM at a single clinic. Patients' progression-free survival (PFS), overall survival (OS), cytogenetics, lines of prior therapy (LOT), and first treatment they received after the development of TCR disease were determined.
RESULTS: The median time from diagnosis to development of TCR disease from diagnosis was 47 months (range: 1.5-191.0; n = 104) and the median LOT prior to TCR disease development was 5 (range: 2-13; n = 117). From the development of TCR disease, patients in our study showed a median OS of 18.9 months (range: 0.03-60.0) and a median PFS of 3.1 months (range: 0.1-55.1). The most commonly utilized first treatment regimens used after TCR disease development were mAb-containing combinations (n = 42). Venetoclax-based regimens showed the longest median PFS at 12.4 months (n = 14).
CONCLUSIONS: This median OS of 18.9 months recorded at a single clinic provides real-world data regarding the survival of TCR MM patients highlighting the need for improvement in prognosis for this subset of patients.